

# Maura Dickler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11185291/publications.pdf>

Version: 2024-02-01

32  
papers

7,308  
citations

236925

25  
h-index

434195

31  
g-index

33  
all docs

33  
docs citations

33  
times ranked

8339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 2666-2676.	27.0	2,865
2	Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 792-799.	1.6	1,285
3	Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100. <i>Journal of Clinical Oncology</i> , 2008, 26, 4672-4678.	1.6	601
4	Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by <i>HER2</i> Immunophenotype and Gene Amplification. <i>Journal of Clinical Oncology</i> , 2001, 19, 2587-2595.	1.6	531
5	Impairment of BRCA1-Related DNA Double-Strand Break Repair Leads to Ovarian Aging in Mice and Humans. <i>Science Translational Medicine</i> , 2013, 5, 172ra21.	12.4	384
6	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ra51.	12.4	276
7	PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K Inhibition. <i>Cancer Cell</i> , 2016, 30, 229-242.	16.8	187
8	Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib. <i>Clinical Cancer Research</i> , 2011, 17, 3490-3499.	7.0	131
9	Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3154-3159.	1.6	121
10	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. <i>JAMA Oncology</i> , 2017, 3, 1043.	7.1	98
11	Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With <i>HER2</i> -Overexpressing Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 281-287.	2.4	86
12	Living with Metastatic Breast Cancer: A Qualitative Analysis of Physical, Psychological, and Social Sequelae. <i>Breast Journal</i> , 2013, 19, 285-292.	1.0	80
13	Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 442-447.	1.6	75
14	Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1428-1437.	6.4	74
15	Randomised trial of expressive writing for distressed metastatic breast cancer patients. <i>Psychology and Health</i> , 2012, 27, 88-100.	2.2	59
16	The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in <i>HER2</i> -Overexpressed/Amplified Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1216-1222.	1.6	56
17	Sexual and Reproductive Health in Cancer Survivors. <i>Seminars in Oncology</i> , 2013, 40, 726-744.	2.2	53
18	Prospective Clinical Trial of <sup>18</sup> F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1037-1042.	5.0	47

#	ARTICLE	IF	CITATIONS
19	A rigorous evaluation of an institutionally-based communication skills program for post-graduate oncology trainees. <i>Patient Education and Counseling</i> , 2018, 101, 1924-1933.	2.2	39
20	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 387-394.	2.4	37
21	Age-Related Decline in DNA Repair Function Explains Diminished Ovarian Reserve, Earlier Menopause, and Possible Oocyte Vulnerability to Chemotherapy in Women With <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2014, 32, 1093-1094.	1.6	34
22	21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 69-76.	2.5	31
23	The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 65-76.	2.5	28
24	Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction. <i>Journal of Clinical Oncology</i> , 2009, 27, 6117-6123.	1.6	26
25	The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by <sup>18</sup> F-FDG PET/CT Using PERCIST. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1102-1104.	5.0	26
26	Bevacizumab for Advanced Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 303-319.	2.2	22
27	Increasing Precision in Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 790-791.	27.0	14
28	The 21-Gene Recurrence Score in Male Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1530-1535.	1.5	14
29	Prolonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible. <i>Clinical Breast Cancer</i> , 2008, 8, 418-424.	2.4	12
30	Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. <i>BMC Cancer</i> , 2018, 18, 42.	2.6	9
31	Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. <i>American Journal of Clinical Pathology</i> , 2020, 153, 149-155.	0.7	7
32	Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 498-499.	4.3	0